Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
KERX positive earnings out. This is huge IMO. 141k traded after hours at a high of .55. Should be fun tommorrow!
NEW YORK, May 13 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer (the "Company"), today announced its results for the first quarter ended March 31, 2009.
At March 31, 2009, the Company had cash, cash equivalents, short-term investment securities and interest receivable of $15.4 million, as compared to $15.5 million at December 31, 2008. In addition, at March 31, 2009, the Company had $7.1 million of auction rate securities which are classified as long-term investments.
The net income for the first quarter ended March 31, 2009 was $451,000, or $0.01 per share, compared to a net loss of $34,536,000, or $0.79 per share, for the first quarter in 2008. The change in net income (loss) was primarily attributable to a $25,894,000 decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008, a $2,671,000 and $344,000 decrease in research and development expenses related to KRX-0401 and Zerenex, respectively, a $3,128,000 increase in license revenue as a result of a $3.0 million milestone payment from JT/Torii, a $1,310,000 increase in interest and other income (expense), net, and an $846,000 decrease in other selling, general and administrative expenses.
Commenting on the quarter, Michael P. Tarnok, the Company's Interim Chairman and Chief Executive Officer, remarked, "We are pleased that the development of Zerenex in Japan continues on schedule and earned us a $3 million milestone payment from JT/Torii, our Japanese partner, for their initiation of a Phase 2 study in Japan. The restructuring initiatives implemented over the last year have resulted in a substantially lower cash burn and we believe that we are sufficiently capitalized to carry out our business plan well into 2010. We are also on track in finding a new chief executive officer who will help us unlock the inherent value of our late-stage clinical pipeline."
On Thursday, May 14, 2009, at 8:30am EDT, the Company will host an investor conference call during which they will provide a brief financial overview of the Company's first quarter financial results and a business outlook for the remainder of 2009.
In order to participate in the conference call, please call 1-877-407-8289 (U.S.), 1-201-689-8341 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com/, for a period of 15 days after the call
KERX positive earnings out. This is huge IMO. 141k traded after hours at a high of .55. Should be fun tommorrow!
NEW YORK, May 13 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer (the "Company"), today announced its results for the first quarter ended March 31, 2009.
At March 31, 2009, the Company had cash, cash equivalents, short-term investment securities and interest receivable of $15.4 million, as compared to $15.5 million at December 31, 2008. In addition, at March 31, 2009, the Company had $7.1 million of auction rate securities which are classified as long-term investments.
The net income for the first quarter ended March 31, 2009 was $451,000, or $0.01 per share, compared to a net loss of $34,536,000, or $0.79 per share, for the first quarter in 2008. The change in net income (loss) was primarily attributable to a $25,894,000 decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008, a $2,671,000 and $344,000 decrease in research and development expenses related to KRX-0401 and Zerenex, respectively, a $3,128,000 increase in license revenue as a result of a $3.0 million milestone payment from JT/Torii, a $1,310,000 increase in interest and other income (expense), net, and an $846,000 decrease in other selling, general and administrative expenses.
Commenting on the quarter, Michael P. Tarnok, the Company's Interim Chairman and Chief Executive Officer, remarked, "We are pleased that the development of Zerenex in Japan continues on schedule and earned us a $3 million milestone payment from JT/Torii, our Japanese partner, for their initiation of a Phase 2 study in Japan. The restructuring initiatives implemented over the last year have resulted in a substantially lower cash burn and we believe that we are sufficiently capitalized to carry out our business plan well into 2010. We are also on track in finding a new chief executive officer who will help us unlock the inherent value of our late-stage clinical pipeline."
On Thursday, May 14, 2009, at 8:30am EDT, the Company will host an investor conference call during which they will provide a brief financial overview of the Company's first quarter financial results and a business outlook for the remainder of 2009.
In order to participate in the conference call, please call 1-877-407-8289 (U.S.), 1-201-689-8341 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com/, for a period of 15 days after the call
KERX positive earnings out. This is huge IMO. 141k traded after hours at a high of .55. Should be fun tommorrow!
NEW YORK, May 13 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer (the "Company"), today announced its results for the first quarter ended March 31, 2009.
At March 31, 2009, the Company had cash, cash equivalents, short-term investment securities and interest receivable of $15.4 million, as compared to $15.5 million at December 31, 2008. In addition, at March 31, 2009, the Company had $7.1 million of auction rate securities which are classified as long-term investments.
The net income for the first quarter ended March 31, 2009 was $451,000, or $0.01 per share, compared to a net loss of $34,536,000, or $0.79 per share, for the first quarter in 2008. The change in net income (loss) was primarily attributable to a $25,894,000 decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008, a $2,671,000 and $344,000 decrease in research and development expenses related to KRX-0401 and Zerenex, respectively, a $3,128,000 increase in license revenue as a result of a $3.0 million milestone payment from JT/Torii, a $1,310,000 increase in interest and other income (expense), net, and an $846,000 decrease in other selling, general and administrative expenses.
Commenting on the quarter, Michael P. Tarnok, the Company's Interim Chairman and Chief Executive Officer, remarked, "We are pleased that the development of Zerenex in Japan continues on schedule and earned us a $3 million milestone payment from JT/Torii, our Japanese partner, for their initiation of a Phase 2 study in Japan. The restructuring initiatives implemented over the last year have resulted in a substantially lower cash burn and we believe that we are sufficiently capitalized to carry out our business plan well into 2010. We are also on track in finding a new chief executive officer who will help us unlock the inherent value of our late-stage clinical pipeline."
On Thursday, May 14, 2009, at 8:30am EDT, the Company will host an investor conference call during which they will provide a brief financial overview of the Company's first quarter financial results and a business outlook for the remainder of 2009.
In order to participate in the conference call, please call 1-877-407-8289 (U.S.), 1-201-689-8341 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com/, for a period of 15 days after the call
KERX, me like
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
Keryx to Host Investor Conference Call on Thursday, May 14, 2009 at 8:30am EDT
NEW YORK, May 13 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer (the "Company"), today announced its results for the first quarter ended March 31, 2009.
At March 31, 2009, the Company had cash, cash equivalents, short-term investment securities and interest receivable of $15.4 million, as compared to $15.5 million at December 31, 2008. In addition, at March 31, 2009, the Company had $7.1 million of auction rate securities which are classified as long-term investments.
The net income for the first quarter ended March 31, 2009 was $451,000, or $0.01 per share, compared to a net loss of $34,536,000, or $0.79 per share, for the first quarter in 2008. The change in net income (loss) was primarily attributable to a $25,894,000 decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008, a $2,671,000 and $344,000 decrease in research and development expenses related to KRX-0401 and Zerenex, respectively, a $3,128,000 increase in license revenue as a result of a $3.0 million milestone payment from JT/Torii, a $1,310,000 increase in interest and other income (expense), net, and an $846,000 decrease in other selling, general and administrative expenses.
Commenting on the quarter, Michael P. Tarnok, the Company's Interim Chairman and Chief Executive Officer, remarked, "We are pleased that the development of Zerenex in Japan continues on schedule and earned us a $3 million milestone payment from JT/Torii, our Japanese partner, for their initiation of a Phase 2 study in Japan. The restructuring initiatives implemented over the last year have resulted in a substantially lower cash burn and we believe that we are sufficiently capitalized to carry out our business plan well into 2010. We are also on track in finding a new chief executive officer who will help us unlock the inherent value of our late-stage clinical pipeline."
On Thursday, May 14, 2009, at 8:30am EDT, the Company will host an investor conference call during which they will provide a brief financial overview of the Company's first quarter financial results and a business outlook for the remainder of 2009.
In order to participate in the conference call, please call 1-877-407-8289 (U.S.), 1-201-689-8341 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com/, for a period of 15 days after the call.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM)(ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also actively engages in business development activities that include seeking strategic relationships for its product candidates and for the Company, as well as evaluating compounds and companies for in-licensing or acquisition. Keryx is headquartered in New York City.
Cautionary Statement
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: There can be no assurance that the Company will satisfy Nasdaq's conditions for continued listing on The Nasdaq Capital Market, that an appeal or hearing for a stay of delisting from The Nasdaq Capital Market will be successful, or that the Company's common stock will remain listed on The Nasdaq Capital Market; that the Company will complete cost-effective clinical trials or meet as anticipated the development timelines for the drug candidates in its pipeline, including Zerenex and KRX-0401, to help generate greater interest in the market for its common stock; that the Company will be able to find suitable partners for some of its drugs under development, or raise additional capital in the future in order to fund its operations; that the Company will be able to locate a suitable chief executive officer who will be able to successfully lead the development of the Company's clinical pipeline; or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com/. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.
KERYX CONTACT: Lauren Fischer Director - Investor Relations Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965 E-mail:
Keryx Biopharmaceuticals, Inc.
Selected Consolidated Financial Data (In Thousands, Except Share and Per Share Amounts)
Statements of Operations Information (Unaudited):
Three Months Ended March 31, 2009 2008 REVENUE: License revenue $ 3,327 $ 199 Service revenue 3 -- TOTAL REVENUE 3,330 199
OPERATING EXPENSES: Research and development: Non-cash compensation 201 (980) Other research and development 1,374 30,827 Total research and development 1,575 29,847
Selling, general and administrative: Non-cash compensation 370 1,717 Other selling, general and administrative 1,041 1,887 Total selling, general and administrative 1,411 3,604
TOTAL OPERATING EXPENSES 2,986 33,451
OPERATING INCOME (LOSS) 344 (33,252)
OTHER INCOME (EXPENSE): Interest and other income (expense), net 107 (1,203)
INCOME (LOSS) FROM CONTINUING OPERATIONS 451 (34,455)
Loss from discontinued operations -- (81)
NET INCOME (LOSS) $ 451 $(34,536)
NET INCOME (LOSS) PER COMMON SHARE Continuing operations $ 0.01 $ (0.79) Discontinued operations -- (--)* Basic and diluted net income (loss) per common share $ 0.01 $ (0.79)
SHARES USED IN COMPUTING NET (INCOME) LOSS PER COMMON SHARE Basic 47,853,895 43,718,077 Diluted 48,050,220 43,718,077
* Amount less than one cent.
Balance Sheet Information:
March 31, 2009 December 31, 2008* (unaudited) Cash, cash equivalents, interest receivable and short-term investment securities $15,446 $15,467 Long-term investment securities 7,117 7,185 Total assets 26,445 26,634 Accumulated deficit (331,467) (331,918) Stockholders' deficit (467) (1,489)
* Condensed from audited financial statements.
DATASOURCE: Keryx Biopharmaceuticals, Inc.
CONTACT: Lauren Fischer, Director, Investor Relations of Keryx
Biopharmaceuticals, Inc., +1-212-531-5965,
Web Site: http://www.keryx.com/
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
Keryx to Host Investor Conference Call on Thursday, May 14, 2009 at 8:30am EDT
NEW YORK, May 13 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer (the "Company"), today announced its results for the first quarter ended March 31, 2009.
At March 31, 2009, the Company had cash, cash equivalents, short-term investment securities and interest receivable of $15.4 million, as compared to $15.5 million at December 31, 2008. In addition, at March 31, 2009, the Company had $7.1 million of auction rate securities which are classified as long-term investments.
The net income for the first quarter ended March 31, 2009 was $451,000, or $0.01 per share, compared to a net loss of $34,536,000, or $0.79 per share, for the first quarter in 2008. The change in net income (loss) was primarily attributable to a $25,894,000 decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008, a $2,671,000 and $344,000 decrease in research and development expenses related to KRX-0401 and Zerenex, respectively, a $3,128,000 increase in license revenue as a result of a $3.0 million milestone payment from JT/Torii, a $1,310,000 increase in interest and other income (expense), net, and an $846,000 decrease in other selling, general and administrative expenses.
Commenting on the quarter, Michael P. Tarnok, the Company's Interim Chairman and Chief Executive Officer, remarked, "We are pleased that the development of Zerenex in Japan continues on schedule and earned us a $3 million milestone payment from JT/Torii, our Japanese partner, for their initiation of a Phase 2 study in Japan. The restructuring initiatives implemented over the last year have resulted in a substantially lower cash burn and we believe that we are sufficiently capitalized to carry out our business plan well into 2010. We are also on track in finding a new chief executive officer who will help us unlock the inherent value of our late-stage clinical pipeline."
On Thursday, May 14, 2009, at 8:30am EDT, the Company will host an investor conference call during which they will provide a brief financial overview of the Company's first quarter financial results and a business outlook for the remainder of 2009.
In order to participate in the conference call, please call 1-877-407-8289 (U.S.), 1-201-689-8341 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com/, for a period of 15 days after the call.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM)(ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also actively engages in business development activities that include seeking strategic relationships for its product candidates and for the Company, as well as evaluating compounds and companies for in-licensing or acquisition. Keryx is headquartered in New York City.
Cautionary Statement
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: There can be no assurance that the Company will satisfy Nasdaq's conditions for continued listing on The Nasdaq Capital Market, that an appeal or hearing for a stay of delisting from The Nasdaq Capital Market will be successful, or that the Company's common stock will remain listed on The Nasdaq Capital Market; that the Company will complete cost-effective clinical trials or meet as anticipated the development timelines for the drug candidates in its pipeline, including Zerenex and KRX-0401, to help generate greater interest in the market for its common stock; that the Company will be able to find suitable partners for some of its drugs under development, or raise additional capital in the future in order to fund its operations; that the Company will be able to locate a suitable chief executive officer who will be able to successfully lead the development of the Company's clinical pipeline; or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com/. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.
KERYX CONTACT: Lauren Fischer Director - Investor Relations Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965 E-mail:
Keryx Biopharmaceuticals, Inc.
Selected Consolidated Financial Data (In Thousands, Except Share and Per Share Amounts)
Statements of Operations Information (Unaudited):
Three Months Ended March 31, 2009 2008 REVENUE: License revenue $ 3,327 $ 199 Service revenue 3 -- TOTAL REVENUE 3,330 199
OPERATING EXPENSES: Research and development: Non-cash compensation 201 (980) Other research and development 1,374 30,827 Total research and development 1,575 29,847
Selling, general and administrative: Non-cash compensation 370 1,717 Other selling, general and administrative 1,041 1,887 Total selling, general and administrative 1,411 3,604
TOTAL OPERATING EXPENSES 2,986 33,451
OPERATING INCOME (LOSS) 344 (33,252)
OTHER INCOME (EXPENSE): Interest and other income (expense), net 107 (1,203)
INCOME (LOSS) FROM CONTINUING OPERATIONS 451 (34,455)
Loss from discontinued operations -- (81)
NET INCOME (LOSS) $ 451 $(34,536)
NET INCOME (LOSS) PER COMMON SHARE Continuing operations $ 0.01 $ (0.79) Discontinued operations -- (--)* Basic and diluted net income (loss) per common share $ 0.01 $ (0.79)
SHARES USED IN COMPUTING NET (INCOME) LOSS PER COMMON SHARE Basic 47,853,895 43,718,077 Diluted 48,050,220 43,718,077
* Amount less than one cent.
Balance Sheet Information:
March 31, 2009 December 31, 2008* (unaudited) Cash, cash equivalents, interest receivable and short-term investment securities $15,446 $15,467 Long-term investment securities 7,117 7,185 Total assets 26,445 26,634 Accumulated deficit (331,467) (331,918) Stockholders' deficit (467) (1,489)
* Condensed from audited financial statements.
DATASOURCE: Keryx Biopharmaceuticals, Inc.
CONTACT: Lauren Fischer, Director, Investor Relations of Keryx
Biopharmaceuticals, Inc., +1-212-531-5965,
Web Site: http://www.keryx.com/
Thats awesome. I hope you took your girl back to the room after that and did the dirty on a pile of $100 bills.
You some kinda wizard or something that can see the future?
RBDC, dump it yet?
EEE, you have a trigger/target for this one?
OK, you threw me here! lol.
Please explain. TIA
EGT going green, breaks .25 and i think were headed back to the .30's
EGT nice buy, volume coming in now, .229
EGT, so tempted to jump back in here, just don't know
EGT, oh I didn't miss it, I was in way before the boards even started talking about it. Ave. 0.108, made a bundle on most of it, looking for re-entry.
EGT, anyone have any thoughts for today? Already showing a trade below yesterdays low at 0.22.
EEE might be coming out of consolidation, in at 1.09
KERX 0.35 x 0.356, that poor bastard that got stopped out at .251 must be crying.
EGT trying to turn up here
EGT done you think? I would think this run was triggered by something coming in the financials Thursday, maybe not????
wtf is this all about?
EGT, f'n whack-a-thon
Got dumped a couple minutes after open, currently .28ish
Nice call, you nailed it. Was involved in to many other stocks and didn't join you.
EGT break .30 finally near EOD and people still whacking it. You got to be a g-damn idiot to be selling this right now, IMO
EGT, Don't count it out yet, plenty of time yet. I could see a major push at EOD in anticipation of a big gap in the a.m.
Yeah, that what i was seeing as .35 as key. Was wondering what AF saw at .38???
Thanks, swung it a couple time a while back and was watching it closely. Traded very odd for a long time. There was a huge seller out there and you could tell by the tape that someone was loading bigly. Ave. at 0.108.
AF, just wondering where your coming up with .38 as a key break? TIA
.
Compare this volume to weeks previous of last week as well. Very impressive!
EGT I don't like to throw out predictions to quick but will say it's definately a possability. It's kind of in wide open territory right now. I've got resistance at .35 and mid to upper .40's ahead. Financials out Thursday are a key element here. Always look to lock in some profit though.
Volume is impressive, suggest this has room to go.
EGT new HOD!
EGT should rock w/ this .22 break
EGT a break of 0.22 should really launch it imo. Coming soon i believe.
KERX bid building, filled gap and tested support. I think it moves back into the 40's today
EGT monster volume! Break .22 and should fly some more
EGT a break of 0.22 should really launch it imo
KERX, gap filled now from the other day. hope this turns and burns now
EGT .20's weeeeeeeeeee!!!
EGT just broke .16 resistnance, should see mid 20's now
Cool, glad to see you guys on EGT. Have swung this a couple times for small profit and currently have a position in the 10's. I've been watching this one for a few months and really thought this would have popped already. Almost loss my patience with it. It trades very "odd". Theres been a huge seller of late but theres big buyers sitting there eating everything up and it appeared Friday that the seller may be done. Volume was impressive. Hope she goes this week